Prostate cancer is the most commonly diagnosed malignancy among men in industrialized countries, accounting for the second leading cause of cancer-related deaths. Although we now know that the androgen receptor (AR) is important for progression to the deadly advanced stages of the disease, it is poorly understood what AR-regulated processes drive this pathology. Here we demonstrate that AR regulates prostate cancer cell growth via the metabolic sensor 5 0 -AMP-activated protein kinase (AMPK), a kinase that classically regulates cellular energy homeostasis. In patients, activation of AMPK correlated with prostate cancer progression. Using a combination of radiolabeled assays and emerging metabolomic approaches, we also show that prostate cancer cells respond to androgen treatment by increasing not only rates of glycolysis, as is commonly seen in many cancers, but also glucose and fatty acid oxidation. Importantly, this effect was dependent on androgen-mediated AMPK activity. Our results further indicate that the AMPK-mediated metabolic changes increased intracellular ATP levels and peroxisome proliferatoractivated receptor gamma coactivator 1-alpha (PGC-1a)-mediated mitochondrial biogenesis, affording distinct growth advantages to the prostate cancer cells. Correspondingly, we used outlier analysis to determine that PGC-1a is overexpressed in a subpopulation of clinical cancer samples. This was in contrast to what was observed in immortalized benign human prostate cells and a testosterone-induced rat model of benign prostatic hyperplasia. Taken together, our findings converge to demonstrate that androgens can co-opt the AMPK-PGC-1a signaling cascade, a known homeostatic mechanism, to increase prostate cancer cell growth. The current study points to the potential utility of developing metabolic-targeted therapies directed toward the AMPK-PGC-1a signaling axis for the treatment of prostate cancer.
INTRODUCTION
Since the 1920s, it has been known that cancer cells possess the unique ability to alter their metabolism and, as such, are distinguishable from benign cells. 1 However, it was only in the past decade that the reprogramming of energy metabolism has been acknowledged as one of the true emerging hallmarks of cancer. 2 Interestingly, although the majority of metabolic cancer research focuses on the role of glycolysis, it has recently become apparent that the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) also have major roles in many types of cancers including prostate cancer. [3] [4] [5] [6] Both the genetic deletion or pharmacological inhibition of key steps in the TCA cycle and/or OXPHOS can block cancer cell growth in vitro and disease progression in vivo. [7] [8] [9] [10] Further, metabolic signatures of the TCA cycle and OXPHOS correlate with cancer progression and unfavorable outcomes. 9, [11] [12] [13] [14] [15] [16] [17] Also, 2-18 F-fluoropropionic acid and 11 C-acetate, new tracers being used for positron emission tomography imaging, are more sensitive detectors of prostate cancer than the glycolysis marker 18 F-fluorodeoxyglucose. [18] [19] [20] [21] These data indicate that prostate cancers can exhibit unique metabolic profiles. What is not understood is specifically how androgen receptor (AR) signaling, elevated in 100% of metastatic prostate cancers, 22 impacts cellular metabolism and what role this has in disease progression.
Prostate cancers express the AR and rely on androgens for growth and survival. 23 Consequently, androgen ablation therapies are the standard of care for late-stage disease. Although patients with advanced prostate cancer initially respond favorably to androgen ablation therapy, most experience a relapse of the disease within 1-2 years. Following this castration-resistant relapse, patients have limited treatment options. Although the hormone-refractory disease is unresponsive to androgen deprivation, AR-regulated signaling pathways remain active and are necessary for cancer progression. 23, 24 Thus, both AR itself and the processes downstream of the receptor remain viable targets for therapeutic intervention. The master metabolic regulator 5 0 -AMP-activated protein kinase (AMPK) governs overall cellular homeostasis by modulating the use of sugars, fats and/or proteins as sources of cellular fuel. Recent work from our laboratory has demonstrated that androgens increase cellular migration and invasion through the direct upregulation of Ca 2 þ /calmodulin-dependent protein kinase kinase-b (CaMKKb) and subsequent threonine-172 (refers to threonine-183/172 of the AMPKa1/AMPKa2 isoforms, respectively) phosphorylation/activation of the catalytic subunit of AMPK. 25 Later, two more independent groups confirmed our CaMKK findings in vitro and in multiple clinical cohorts, and suggested that CaMKKb also promotes glycolytic flux. 26, 27 Correspondingly, Park et al. 28 demonstrated that levels of the serine-79 phosphorylated form of acetyl-CoA carboxylase, a direct target of AMPK, are increased in clinical prostate cancer samples. Because of the importance of androgen signaling in prostate cancer, and the increasing evidence from other laboratories as well as our own that suggest AMPK may have an oncogenic role in certain cancer contexts, [25] [26] [27] [28] [29] [30] [31] we wanted to determine whether AR signaling promoted prostate cancer cell growth in part through AMPK signaling. Further, given AMPK's role as a central regulator of cellular metabolism, we also wanted to determine whether ARmediated AMPK signaling influenced prostate cancer cell biology through additional mechanisms beyond those classically attributed to cancer (that is, glycolysis).
RESULTS
AMPK is required for androgen-mediated prostate cancer cell growth Our previous work identified a role for CaMKKb-AMPK signaling in AR-mediated prostate cancer cell migration and invasion. 25 Subsequent studies confirmed AR's regulation of CaMKKb in prostate cancer and demonstrated its additional importance in regulating prostate cancer growth both in vitro and in vivo. 26, 27 In addition, Massie et al. 27 showed that CaMKKb augmented cell growth in part through increased glucose metabolism, an effect they suggested may be mediated through AMPK. In that study, the role of AMPK was inferred from experiments that used pharmacological AMP mimetics that, while known activators of AMPK, cause cellular stress and therefore may indirectly affect cell growth. Because of these and other known pleiotropic effects of various AMPK modulators (for example, compound C blocks AR activity 25 ), we wanted to confirm a direct role for AMPK in AR-mediated prostate cancer cell growth using molecular approaches. To do so, we blocked AMPK activity using small interferring RNAs (siRNAs) targeting three separate regions of the predominant catalytic subunit of AMPK found in the prostate. 25 In both LNCaP and VCaP human prostate cancer cells, siRNA-mediated knockdown of AMPKa1 decreased the levels of both total AMPKa and the threonine-172/activation loop phosphorylated form of AMPKa, indicating blocked AMPK activity (Figures 1a and b) . Importantly, all three siRNAs targeting AMPK significantly inhibited R1881 (a synthetic androgen)-mediated prostate cancer cell growth in both cell types ( Figures  1c and d) , an effect that was observed by 3 days (Supplementary Figure S1 ).
Phosphorylated/activated AMPK correlates with prostate cancer progression in patients A tissue microarray (TMA) containing benign and primary cancer tissues was examined by immunohistochemistry to determine whether phospho-AMPK (Thr172), the activating phosphorylation site, was increased in prostate cancer ( Figure 2 ). The staining of p-AMPK in the TMA was quantified using a multiplicative staining index of intensity (0-3) and extent (0-3) of staining, which yields a 10-point staining index (0-9) as described previously. [32] [33] [34] In benign tissues, weak staining (score 3) was observed in luminal cell cytoplasm in some tissues, with other tissues showing no staining. Occasional tissues showed moderate staining (score 6). In all cases, staining was uniform within each core. Variable cytoplasmic staining was seen in the cancer cells in different tissues ranging from no staining to strong staining (score 9). Overall, staining was significantly stronger in cancer (Figure 2a) . Occasional weak staining was seen in stromal cells in both benign and cancer tissues. Of note, higher p-AMPK staining was significantly correlated with biochemical (prostate-specific antigen (PSA)) recurrence following radical prostatectomy (non-recurrent 3.2 ± 0.4 (mean ±-s.e.m., n ¼ 29) versus recurrent 4.6 ± 0.4 (n ¼ 32)) (Figure 2b ). The p-AMPK immunohistochemistry score was not correlated with pathological variables such as Gleason score or disease stage at the time of surgery.
Androgens promote both glycolysis and OXPHOS Given AMPK's role as a master regulator of metabolism and its regulation by AR in the prostate, we next asked what effects androgens had on prostate cancer cell metabolism. To quantitate glycolytic rates, we measured the extracellular acidification rate (ECAR) in prostate cancer cells following treatment with R1881. In both LNCaP and VCaP cells, R1881 increased glycolysis in a dosedependent manner (Figures 3a-c) . Consistent with what has previously been shown, 35 the dose response was unaffected by various modulators of mitochondrial function (Figure 3c ), highlighting the cytoplasmic nature of glycolysis. Interestingly, simultaneous measurement of the oxygen consumption rate (OCR) indicated that androgens also increased oxygen consumption in a dose-dependent manner (Figures 3d-f ). This androgenmediated increase in OCR was dependent on mitochondrial function, as combined treatment of rotenone and antimycin, inhibitors of mitochondrial respiration, collapsed the response (Figure 3f ). The increased oxygen consumption indicated that androgens promote metabolism not only through glycolysis but also through the TCA cycle. In support of this, we used tandem mass spectrometry (MS/MS) to show that androgens increased intracellular levels of acetyl-CoA, the entry molecule for the TCA cycle (Figure 3g ). Importantly, gas chromatography/mass spectrometry (GC/MS) was used to demonstrate that androgens also increased the levels of all TCA cycle intermediates tested, suggesting that acetyl-CoA is not only entering the TCA cycle but is also metabolized completely through it (Figure 3h ). These data are in contrast to the reports of Massie et al. 27 who found that androgen treatment increased citrate but not succinate levels nor oxygen consumption. To verify whether complete oxidation was occurring, we used a radiolabeled CO 2 trap assay to demonstrate that androgens increase complete glucose oxidation (Figure 3i ; Supplementary Figure S2A ). These results indicate that androgens promote the uptake and metabolism of radiolabeled glucose through at least B1.5 turns of the TCA cycle before the radiolabeled 1-carbon of glucose is being released in the form of CO 2 .
Although the majority of metabolic cancer research focuses on the role of glucose, recently, several groups have demonstrated an important role of fatty acid metabolism in prostate cancer. 18, [36] [37] [38] Correspondingly, in our hands, b-oxidation was required for maximal androgen-mediated prostate cancer cell growth as co-treatment with etomoxir, an inhibitor of carnitine palmitoyltransferase I-the rate-limiting step of b-oxidation, suppressed androgen-mediated LNCaP growth ( Figure 3j ). We therefore tested whether androgens could also promote fatty acid oxidation in prostate cancer cells by tracking the metabolism of radiolabeled fatty acids. Treatment of either LNCaP (Figures 3k and l) or VCaP (Supplementary Figures S2B and C) cells with increasing concentrations of androgens promoted, in a dose-dependent manner, the complete oxidation of both the saturated fatty acid palmitate and the monounsaturated fatty acid oleate, two of the most common b-oxidation substrates. Importantly, this correlates with previous clinical data demonstrating the increased metabolism of both sugars and fats in aggressive metastatic prostate cancers compared with localized tumors. 39 Taken together, these findings indicate that androgens increase both glycolysis (sugars) and OXPHOS (sugars and fats) in prostate cancer cells.
AMPK is required for androgen-mediated OXPHOS AMPK is a positive regulator of OXPHOS. Given that AMPK is required for androgen-mediated prostate cancer cell growth (Figure 1 One of the major functions of mitochondrial OXPHOS is to generate ATP. We therefore wanted to determine whether the androgen-mediated OXPHOS indeed led to an increase in intracellular ATP levels and hence, helped fulfill the cancer cell's bioenergetic demands. Using a luciferase-based ATP assay, we determined that R1881 increased intracellular ATP levels in a dosedependent manner (Figure 5a ). This R1881-mediated increase in ATP levels was blocked by transfection with the siRNAs targeting Androgen-mediated AMPK signaling increases peroxisome proliferator-activated receptor gamma coactivator-1a levels, which are elevated in a subpopulation of prostate cancers Our data indicate that androgens increase overall mitochondrial function. However, the mechanism for this effect was still unknown. One of the known targets of AMPK is peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1a), a transcriptional coactivator that is a master regulator of mitochondrial biogenesis and function. 40 Therefore, we tested whether androgens could increase PGC-1a levels in prostate cancer cells. Androgens, starting at 100 pM significantly increased PGC-1a protein levels in a dose-dependent manner in both LNCaP Figure S3) . Interestingly, despite the robust expression of AR, androgens did not significantly alter PGC-1a levels in a stepwise genetic model of prostate cancer progression 41 (Supplementary Figure S4) . This is not completely surprising given (1) the heterogeneous nature of prostate cancer and (2) in culture, none of these cells display an androgen-mediated growth response. 41 However, using a hormone-inducible rat model of benign prostatic hyperplasia, we observed that although testosterone treatment increased prostate growth, 42, 43 it did not Figure 1 . (k and l) LNCaP cells were treated and subjected to a CO 2 trap assay the same as in i, but using 14 C-labeled palmitate (k) or oleate (l) to quantitate the levels of fatty acid oxidation. '*' denotes significant changes from vehicle-treated cells.
increase PGC-1a protein levels (Supplementary Figure S5) . This is in contrast to the increased PGC-1a levels observed in tumors derived from the dorsolateral lobes of the well-characterized PbCre, Pten f/f mouse model of prostate cancer 44 (Supplementary Figure S6) or the Pb-Myc mouse model of prostate cancer. 45 In addition, comparison of parental LNCaP cells with their castrationresistant prostate cancer (CRPC)-derivative C4-2 cell line (derived from castration-resistant selection in xenografts) demonstrates that p-AMPK and, accordingly, PGC-1a levels are markedly elevated in the CRPC C4-2 model relative to parental LNCaPs (Figure 6e ). Xenograft-derived LAPC9 tumors that were either propagated in intact mice or serially propagated for 13 generations in castrated mice revealed that, despite decreased AR levels, PGC-1a levels are maintained, and surprisingly, total AMPK and, subsequently, p-AMPK levels are increased in the CRPC model (Figure 6e ). Although this is the first time we had observed changes in total AMPK levels, it is important to note that AMPKa1/ PRKAA1 (the predominant isoform of the catalytic subunit of AMPK expressed in the prostate 25 ) levels correlate with poor prognosis in patients (Supplementary Figure S7) . 22 These findings corroborate the clinical p-AMPK TMA data shown in Figure 2 . Taken together, our results suggest that AMPK-PGC-1a signaling correlates with cancer growth and can be indirectly regulated by AR.
To test whether AMPK was responsible for the androgenmediated increase in PGC-1a levels, we used the same siRNAs targeting AMPK described in Figure 1 to determine what effects they had on both basal and androgen-mediated PGC-1a levels (Figures 6f and g; Supplementary Figure S8) . In LNCaP and VCaP cells, knockdown of AMPK led to a significant decrease in both PGC-1a protein (Figure 6f; Supplementary Figures S8A and B) and mRNA (Figure 6g; Supplementary Figure S8C ) levels, demonstrating a clear requirement for AMPK in AR-mediated induction of OCRs were then measured using the Seahorse analyzer and normalized to cell numbers as described in Figure 3 . LNCaP (c, e, g) or VCaP (d, f, h) cells were transfected and treated as described in a and b. Oxidation of radiolabeled glucose (c and d), palmitate (e and f ) and oleate (g and h) were then measured using CO 2 trap assays and normalized to cell numbers as in Figure 3 . '*' denotes significant changes from vehicle-treated cells.
PGC-1a. Finally, stable knockdown of PGC-1a suppressed prostate cancer cell growth/survival over 3 days roughly 40% in LNCaP cells (Supplementary Figure S8D) and, importantly, 50% in the CRPC C4-2 model (Figure 6h ), highlighting a potential role for PGC-1a in the advanced disease.
Given that PGC-1a levels were increased in multiple models of prostate cancer, we next determined whether its expression correlated with prostate cancer in patients. Analysis of clinically annotated prostate cancer data sets accessible through Oncomine revealed that PGC-1a expression was significantly higher in cancers compared with controls (Supplementary Figure S9A) . 46 Although this increase was significant, it was derived from a study with a modest cohort size (19 patients). Because of the high degree of heterogeneity in prostate cancer, we asked whether PGC-1a levels might be elevated in a subset of cancers. Using outlier analysis, we found that PGC-1a was indeed overexpressed in a subpopulation of prostate cancers in multiple clinical cohorts (Supplementary Figure S9B) . [46] [47] [48] [49] [50] To better clinically define this subset of patients, we took advantage of the emerging wellannotated data sets available from The Cancer Genome Atlas. Here, PGC-1a is significantly overexpressed in B5% of prostate cancer patients (no patients had significantly decreased expression). These patients exhibited clinical pathologic T stages from T2c to T3b and Gleason scores from 7 to 9 with a mean of 7.4. Interestingly, patients from this subpopulation are initially diagnosed with prostate cancer significantly earlier (56.0 ± 1.5 year old versus 60.2 ± 0.5 years for the average prostate cancer patient).
AR-AMPK-PGC-1a signaling promotes mitochondrial biogenesis and cell growth Mitochondrial function is essential for both basic cellular homeostasis as well as increased cell growth. 51 Given recent studies that suggest a previously underappreciated role for mitochondrial function in cancer, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] we decided to test whether androgens could increase mitochondrial biogenesis in prostate cancer cells. Using transmission electron microscopy, we found that LNCaP cells treated for 72 h had significantly more mitochondria (Figure 7a ). To test whether the AMPK-mediated induction of PGC-1a promoted androgen-mediated mitochondrial biogenesis in a more unbiased manner, we used confocal microscopy and subsequent image analysis to quantitatively assess whether AMPK and/or PGC-1a were required (Figures 7b-d ; Supplementary  Figures S10 and 11 ). Using our two most efficacious siRNAs targeting AMPK 25 or PGC-1a (Supplementary Figure S11) , siRNAmediated knockdown of either AMPK or PGC-1a significantly decreased mitochondrial volume in LNCaP and VCaP cells (Figures  7b-d; Supplementary Figures S10 and 11 ). Similar to knockdown of AMPK (Figures 1 and 4) , molecular inhibition of PGC-1a also blocked androgen-mediated OXPHOS (Figure 7e ) and, in concordance with what others have reported, 52 prostate cancer cell growth (Figure 7f ), an effect that was observed by 3 days (Supplementary Figures S11C and D) . However, it should be noted that unlike what has previously been reported, 52 in our hands PGC-1a did not feedback to further potentiate AR activity (Supplementary Figure S12) . Collectively, these results indicate a role for a more linear AR-AMPK-PGC-1a signaling cascade in prostate cancer cell growth.
DISCUSSION
Although much of the research on cancer metabolism has historically focused on glycolysis, it is now becoming apparent that not all cancers depend solely on glycolytic metabolism. Prostate cancer, in particular, appears to utilize other processes to fulfill its metabolic demands. Accordingly, the glycolysis marker 18 F-fluorodeoxyglucose is a relatively poor positron emission tomography imaging marker for prostate cancer. 18, 19 Conversely, labeled fatty acid and acetate analogs, which can be shuttled to fatty acid metabolism and/or enter the TCA cycle, have shown more promising results. 18, 20, 21 Interestingly, zinc and citrate levels are higher in normal prostate epithelial cells than any other cell in the body. When prostate epithelial cells become cancerous, they are uniquely characterized by decreased zinc and citrate levels, which parallels with increased citrate oxidation and OXPHOS. 5, 6 Further, mitochondrial biogenesis, TCA cycle and OXPHOS signatures correlate with unfavorable outcomes in prostate cancer as well as other cancer types. 3, 11, 13, 15, 16, [53] [54] [55] [56] The inhibition of mitochondrial function/OXPHOS results in cell death or cell cycle arrest in multiple cancer types. [8] [9] [10] 17 Thus, while glycolysis is a major metabolic pathway in cancer, mitochondrion-mediated functions still appear essential for many cancer cell types including prostate.
The findings above suggest that mitochondria could be an important target for various oncogenic and tumor suppressor signaling cascades. Correspondingly, the telomerase oncogene promotes mitochondrial biogenesis and prostate cancer bone metastasis while the tumor suppressor p53 suppresses PGC-1-mediated mitochondrial biogenesis. 13, 54, 55 Our data presented here indicate that AR signaling also increases AMPK-PGC-1-mediated mitochondrial biogenesis and prostate cancer cell growth (Figure 7) . This raises the question of how mitochondrial Figure 3g . ATP levels were then quantitated using a luciferase-based assay and data were normalized to cell numbers. Results are expressed as relative ATP levels normalized to cell numbers þ s.e. (n ¼ 3). (b) Cells were transfected and treated as in Figure 1a . ATP levels were then quantitated and normalized as in a. '*' denotes significant changes from vehicle-treated cells.
biogenesis contributes to cell growth. One obvious possibility is that rapidly dividing cells have high bioenergetic demands. By increasing the mitochondrial content of the cell, androgens also increased the intracellular levels of ATP ( Figure 5) . Recently, however, it has been determined that the level of building blocks (for example, amino acids for protein production and so on), rather than the level of ATP, may be the major rate-limiting factor for rapidly dividing cells. 4 As such, making sure a high level of TCA cycle intermediates are maintained, a process termed anaplerosis, would be essential as the TCA cycle serves as a central metabolic hub from which many of the cellular building blocks are derived (Figure 8 ). Our findings that androgens increase TCA cycle intermediate levels and promote the metabolism of glucose and fatty acids through the TCA cycle (Figure 3) , suggest that AR signaling is also anaplerotic. Current studies are ongoing to determine where substrates are ultimately shuttled following androgen treatment.
The data presented here indicate that AMPK signaling is required for androgen-mediated prostate cancer cell growth and is elevated in prostate cancer and, importantly, recurrent prostate cancer (Figures 1 and 2 ). To date, the role of AMPK in cancer has been enigmatic. We (data not shown), and others, 57 have demonstrated that 5-aminoimidazole-4-carboxamide 1-b-D-ribofuranoside (AICAR) and the antidiabetic drugs metformin and were subjected to a 3-day cell growth/viability assay. Inset, western blot control demonstrating PGC-1a stable knockdown. '*' denotes significant change from shControl cells.
rosiglitazone, which all activate AMPK, also inhibit prostate cancer cell growth. Conversely, although Massie et al. 27 also found that metformin inhibited LNCaP cell growth, they showed AICAR increased LNCaP cell growth in the presence or absence of androgens. In addition, AICAR was able to rescue the growth inhibitory effects of either CaMKKb RNAi knockdown or STO-609 (CaMKK antagonist) treatment. Further, AMPK has been shown to be activated in clinical prostate cancer samples and inhibition of its activity by compound C or siRNAs targeting AMPK blocks cancer cell growth (Figures 1 and 2) . 28 These discrepancies may be because of the pleiotropic effects of the various small molecules being used to modulate AMPK activity. For example, AICAR functions by inducing cellular stress. One of the results of this increased cellular stress is the activation of AMPK. However, the widespread increase in cellular stress may undoubtedly function to inhibit cellular growth through other stress signaling pathways. Alternatively, the pro-growth effects of AMPK may, similar to many signaling cascades, occur within a defined window of activity in which some controlled AMPK activity promotes a metabolic shift that enhances cell growth but too much AMPK activity signals stress and subsequent cell cycle arrest.
In prostate cancer cells, androgens increase PGC-1a protein and mRNA levels (Figures 6a-d) . Although we know that AMPK is required for this PGC-1a regulation (Figures 6f and g ; Figure S10 ) and quantitated morphometric analysis (Figures 7c and d) . Scale bar, 10 mm. (e) LNCaP cells were transfected with indicated siRNAs and treated as described in d. Oxidation of radiolabeled glucose was then measured using a CO 2 trap assay and normalized to cell numbers as in Figure 4 . '*' significant changes from vehicle-treated cells. (f ) LNCaP cells were transfected as in e and then treated for 7 days with doses of ± R1881. Relative cell numbers were determined using the assay described in Figure 1 . '*' denotes significant changes from vehicle-treated cells.
Supplementary Figure S8) , we still do not understand the exact mechanism. Previously, Bruce Spiegelman's laboratory demonstrated that AMPK increases both PGC-1a protein and mRNA levels in skeletal muscle. 40 In that study, they found that AMPK directly phosphorylates PGC-1a on threonine-177 and serine-538. These phosphorylation events then increase the activity of PGC-1a protein on its own promoter, increasing its expression through a mechanism that may involve the transcription factors GATA-4 and Upstream Stimulatory Factor-1. 58 Hence, the AR-AMPK-mediated increase in PGC-1a protein and mRNA levels may occur through the direct post-translational phosphorylation of PGC-1a protein by AMPK and subsequent positive feedback expression of the PPARGC1A gene.
Our data correlate with recent findings that indicate PGC-1a signaling is upregulated in endometrial cancer, 12 drives breast cancer tumor growth in vivo, 59 and Pgc1a À / À mice are resistant to chemically induced models of colon and liver cancer. 7 Correspondingly, Shiota et al. 52 also demonstrated that PGC-1a was essential for prostate cancer cell growth. Interestingly, in that study, PGC-1a was shown to function as a coactivator of AR. In our hands, we did not observe this effect (Supplementary Figure S12) . Thus, our current data indicate AR, via AMPK, increases PGC-1a levels in a more linear manner (Figure 8 ). Whether AMPK and PGC1a promote cancer cell growth through additional mechanisms remains to be determined. Hence, while AMPK-PGC-1a signaling promotes prostate cancer cell growth in part through increasing mitochondrial function (known because inhibition of mitochondrial function decreases cell growth/survival (Figure 3j) ), 10 AMPK-PGC-1a signaling may also enhance prostate cancer cell growth through additional, mitochondrion-independent mechanisms (for example, increasing cyclin D levels and so on). This could also help explain why knockdown of PGC-1a had a more dramatic effect on cell growth (Figure 7f; Supplementary Figures S11C and D) than it did on mitochondrial biogenesis (Figures 7b-d ; Supplementary  Figures S10 and 11) . The more modest effects on mitochondrial biogenesis were likely because of the suboptimal efficacy of our PGC-1a-targeting siRNAs (Supplementary Figure S11) . Conversely, the dramatic effect of molecular PGC-1a inhibition on growth suggests that PGC-1a may potentiate androgen-mediated prostate cancer cell growth through additional mechanisms.
As a result, the modest inhibition of a single protein, PGC-1a, would result in pronounced overall growth effects.
Collectively, the data presented here suggest that AR signaling promotes AMPK-PGC-1a-mediated mitochondrial biogenesis and cell growth. This is important because while AR's role in prostate cancer has been well established, the mechanisms by which AR manifests its biological actions and how these are dysregulated during disease progression are poorly understood. As a result, it is essential to identify the AR signaling networks that truly drive disease progression. Our understanding of these signaling pathways will ultimately yield new therapeutic targets. Hence, as our data indicate, modulators of mitochondrial function may offer new therapeutic avenues for AR-driven prostate cancer.
MATERIALS AND METHODS

Reagents and standard biochemical and molecular approaches
More detailed descriptions of reagents, cell culture, siRNA transfections, western blot analyses, proliferation assays, radiolabeled CO 2 trap assays, ATP assays, real-time PCR analyses, microscopy, viability assays and reporter gene assays are provided in the Supplementary Information.
Human tissues and TMA
Prostate cancer TMAs were constructed using tissues collected after radical prostatectomy with informed consent by the Baylor College of Medicine Human Tissue Acquisition and Pathology Core under an institutional review board (IRB)-approved protocol. The arrays were 1 mm cores of 80 cancers and matched benign tissues with equal numbers of cases with and without biochemical recurrence. Arrays stained with anti-phospho-AMPK antibody were carried out as described in the Supplementary Material and quantitated using a multiplicative staining index of intensity (0-3) and extent (0-3) of staining yielding a 10-point staining index (0-9) as described in previous publications. [32] [33] [34] Some cancer cores could not be scored due to exhaustion of tumor in the core and likewise in some cores no benign epithelium was present. Overall 61 cancers and 65 benign tissues could be scored. Scoring was performed without knowledge of the corresponding clinical and pathological variables.
ECAR and OCR measurements ECAR, reflective of the rate of glycolysis, and OCR, reflective of the rate of OXPHOS, were measured using a Seahorse Bioscience XF24 analyzer (Seahorse Bioscience, North Billerica, MA, USA). Cells were plated at 30 000 cells/well in Seahorse XF24 plates coated with BD Cell-Tak (BD Biosciences, Bedford, MA, USA) and incubated for 48 h. For R1881 dose-response experiments, the cells were then treated for 72 h. For knockdown experiments, cells were transfected with indicated siRNAs overnight before treatment. For ECAR and OCR measurements in the presence of inhibitors (oligomycin-1.3 mM; carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) 1 mM; rotenone 1 mM; antimycin A 1 mM), the samples were treated with R1881 and then incubated for 72 h. During the initial/ basal phase of assaying, no inhibitors were present. Thereafter, at respective time points inhibitor-containing media were sequentially injected to the assay wells through automated instrument ports. Data were normalized to cell numbers using the DNA content assay described in the Supplementary Information.
Metabolic profiling
Measurements of intracellular acetylcarnitine levels, which are reflective of acetyl-CoA levels, and organic acid/TCA cycle intermediates were performed using MS/MS or GC/MS as previously described. 60 Animal studies ARR2PB-Cre (Pb-Cre) transgenic mice 61 were obtained from Dr Fen Wang (Texas A&M Health Science Center, Houston, TX, USA). Pten f/f mice 44 were obtained from Dr Hong Wu (University of California, Los Angeles, CA, USA). Breeding, crosses, dissociation of prostate tumors and RNA isolation were performed using previously described approaches. 62 Adult male Wistar rats (Charles River Laboratories, Wilmington, MA, USA) between 10 and 11 weeks of age were used as a testosterone-induced model of benign prostatic hyperplasia as previously described. Housing Figure 8 . Proposed model of the AR-AMPK-PGC-1a signaling axis. Androgens, through AR, increase AMPK activity. AMPK then potentiates PGC-1a. Increased PGC-1a can then promote mitochondria biogenesis and function.
conditions, treatments and isolation of ventral prostates were previously described. 42, 43 All animals remained healthy throughout the experiments. Animal care was in accordance with institutional guidelines and complied with National Institutes of Health (NIH) policy.
Statistical analysis
Two-sample comparisons were performed using Student's t-tests. Multiple comparisons were performed using a one-way analysis of variance and post hoc Dunnett's test with GraphPad Prism, Version 4 (GraphPad Software, La Jolla, CA, USA). TMA staining intensity groups were compared using Mann-Whitney tests. Kaplan-Meier curves were compared using a log-rank test. Significant changes were determined at the Po0.05 level unless otherwise noted.
